Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study

摘要: Background Validity is the ability of an instrument to measure what it claims measure. It means degree which empirical evidence supports trustworthiness interpretations based on calculated scores. The hematological malignancy (HM) specific patient reported outcome (HM-PRO), a newly developed for use in daily clinical practice as well research. This study, provides construct validity HM-PRO, specifically focusing convergent and divergent compared other established instruments used hematology. Methods validation study adopted prospective cross-sectional design where heterogeneous group patients diagnosed with different HMs disease state were recruited. A total 905 recruited from seven secondary care hospitals UK online through five organizations. Patients asked complete HM-PRO cancer PRO's, FACT-G EORTC QLQ C-30. Data analysis was performed using IBM SPSS 23 statistical software. Results 486 males (53.7%) 419 females (46.3%), mean age 64.3 (± 12.4) years time since diagnosis 4.6 ( ± 5.2) score Part highly correlated functional scales QLQ-C30 (Physical = -0.71, Role -0.72, Emotional -0.64, Cognitive -0.58, Social -0.74-p < 0.001). With respect correlation FACT-G, Physical (-0.74), (-0.57), Functional (-0.66) domains overall (-0.74). Similarly, B three symptoms (Fatigue scale -0.74, Nausea Vomiting -0.52, Pain -0.59-p 0.001) individual symptom items (Dyspnea 0.51, Insomnia= 0.43, Appetite loss 0.54-p Conclusion presented this research testimony HM-PRO's HRQoL issues intends utmost importance when PRO routine so that interpretation scores or response item understood by clinicians/nurses intended patients.